Author
Listed:
- Wen Pan
(State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine
Joint Molecular Rheumatology Laboratory of the Institute of Health Sciences and Shanghai Renji Hospital, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, and Shanghai Jiaotong University School of Medicine
Yale University School of Medicine)
- Shu Zhu
(Yale University School of Medicine)
- Dai Dai
(State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine
Joint Molecular Rheumatology Laboratory of the Institute of Health Sciences and Shanghai Renji Hospital, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, and Shanghai Jiaotong University School of Medicine)
- Zheng Liu
(MedImmune LLC)
- Dan Li
(Institute Pasteur of Shanghai, Chinese Academy of Sciences)
- Bin Li
(Institute Pasteur of Shanghai, Chinese Academy of Sciences)
- Nicola Gagliani
(Yale University School of Medicine)
- Yunjiang Zheng
(Yale University School of Medicine)
- Yuanjia Tang
(State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine
Joint Molecular Rheumatology Laboratory of the Institute of Health Sciences and Shanghai Renji Hospital, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, and Shanghai Jiaotong University School of Medicine)
- Matthew T. Weirauch
(Cincinnati Children's Hospital Medical Center)
- Xiaoting Chen
(School of Electronic and Computing Systems, University of Cincinnati)
- Wei Zhu
(MedImmune LLC)
- Yue Wang
(MedImmune LLC)
- Bo Chen
(MedImmune LLC)
- Youcun Qian
(State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine)
- Yingxuan Chen
(Renji Hospital, Shanghai Institute of Digestive Disease, Shanghai Jiaotong University School of Medicine)
- Jingyuan Fang
(Renji Hospital, Shanghai Institute of Digestive Disease, Shanghai Jiaotong University School of Medicine)
- Ronald Herbst
(MedImmune LLC)
- Laura Richman
(MedImmune LLC)
- Bahija Jallal
(MedImmune LLC)
- John B. Harley
(Cincinnati Children's Hospital Medical Center
US Department of Veterans Affairs Medical Center)
- Richard A. Flavell
(Yale University School of Medicine)
- Yihong Yao
(MedImmune LLC)
- Nan Shen
(State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine
Joint Molecular Rheumatology Laboratory of the Institute of Health Sciences and Shanghai Renji Hospital, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, and Shanghai Jiaotong University School of Medicine
Cincinnati Children's Hospital Medical Center
Collaborative Innovation Center of Systems Biomedicine, Shanghai Jiaotong University)
Abstract
Although different autoimmune diseases show discrete clinical features, there are common molecular pathways intimately involved. Here we show that miR-125a is downregulated in peripheral CD4+ T cells of human autoimmune diseases including systemic lupus erythematosus and Crohn’s disease, and relevant autoimmune mouse models. miR-125a stabilizes both the commitment and immunoregulatory capacity of Treg cells. In miR-125a-deficient mice, the balance appears to shift from immune suppression to inflammation, and results in more severe pathogenesis of colitis and experimental autoimmune encephalomyelitis (EAE). The genome-wide target analysis reveals that miR-125a suppresses several effector T-cell factors including Stat3, Ifng and Il13. Using a chemically synthesized miR-125a analogue, we show potential to re-programme the immune homeostasis in EAE models. These findings point to miR-125a as a critical factor that controls autoimmune diseases by stabilizing Treg-mediated immune homeostasis.
Suggested Citation
Wen Pan & Shu Zhu & Dai Dai & Zheng Liu & Dan Li & Bin Li & Nicola Gagliani & Yunjiang Zheng & Yuanjia Tang & Matthew T. Weirauch & Xiaoting Chen & Wei Zhu & Yue Wang & Bo Chen & Youcun Qian & Yingxua, 2015.
"MiR-125a targets effector programs to stabilize Treg-mediated immune homeostasis,"
Nature Communications, Nature, vol. 6(1), pages 1-12, November.
Handle:
RePEc:nat:natcom:v:6:y:2015:i:1:d:10.1038_ncomms8096
DOI: 10.1038/ncomms8096
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:6:y:2015:i:1:d:10.1038_ncomms8096. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.